IP Library Granted Patent US 9,944,695
Granted Patent B2
US 9,944,695 · App. 14/266,540 · Granted Apr 17, 2018

Antibody producing non-human mammals

Inventors: Ton Logtenberg (Utrecht, NL); Mark Throsby (Utrecht, NL); Robert A. Kramer (Utrecht, NL); Rui Daniel Pinto (Utrecht, NL); Cornelis A. De Kruif (Utrecht, NL); Erwin Houtzager (Zeist, NL)
Assignee: Merus N.V.
C07K16/1282A01K67/027A01K67/0278C07K14/47C07K16/248C12N15/8509C12P21/00A01K2207/15A01K2217/052A01K2217/075A01K2217/15A01K2217/206A01K2227/105A01K2267/01C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,944,695
App. No.
14/266,540
Granted
Apr 17, 2018
Kind
B2
Abstract

Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

Claims (28)

1. A method of obtaining an antibody that binds to an antigen, the method comprising

(a) immunizing a transgenic mouse with the antigen, wherein the genome of the transgenic mouse comprises a transgene comprising a human immunoglobulin light chain germline V gene segment fused to a human immunoglobulin light chain germline J gene segment such that there is no mutation due to said fusion, wherein the fused human V/J gene segments encode a rearranged human immunoglobulin light chain variable region and

wherein the transgene is inserted by site-specific integration in the murine Rosa locus or wherein said transgene lacks the intronic light chain enhancer MoEκi or comprises a truncation of the transgene 3′ kappa enhancer or combination of these,

wherein the transgene comprises a murine light chain constant region gene segment or is operatively linked to an endogenous mouse light chain constant region gene segment; and

wherein if the transgene is inserted by site-specific integration in the murine Rosa locus, the transgene comprises a murine light chain constant region gene segment;

(b) obtaining a population of B cells producing antigen specific antibodies from the transgenic mouse, wherein said antibodies comprise the rearranged human light chain immunoglobulin variable region encoded by the fused human V/J gene segments and a murine constant region paired with a heavy chain variable region encoded by a rearranged and somatically hypermutated VH gene; and

wherein the population of B cells producing antigen specific antibodies from the transgenic mouse comprise a diversity of clonally unrelated rearranged immunoglobulin heavy chain variable regions that bind to the antigen;

(c) isolating nucleic acid encoding a rearranged immunoglobulin heavy chain variable region from a B cell in said population;

(d) expressing nucleic acids encoding the rearranged immunoglobulin heavy chain variable region and at least the rearranged human immunoglobulin light chain variable region in a host cell; and

(e) thus obtaining an antibody which binds to the antigen.

2. A method of obtaining an antibody that binds to an antigen, the method comprising

(a) immunizing a transgenic mouse with the antigen, wherein the genome of the transgenic mouse comprises a transgene comprising a human immunoglobulin light chain germline V gene segment fused to a human immunoglobulin light chain germline J gene segment such that there is no mutation due to said fusion, wherein the fused human V/J gene segments encode a rearranged human immunoglobulin light chain variable region and

wherein the transgene is inserted by site-specific integration in the murine Rosa locus or wherein said transgene lacks the intronic light chain enhancer MoEκi or comprises a truncation of the transgene 3′ kappa enhancer or combination of these; and

wherein the transgene comprises a murine light chain constant region gene segment or is operatively linked to an endogenous mouse light chain constant region gene segment; and

wherein if the transgene is inserted by site-specific integration in the murine Rosa locus, the transgene comprises a murine light chain constant region gene segment;

wherein said transgenic mouse, in response to said antigen, produces mature B cells that produce antibodies with immunoglobulin light chains comprising said encoded rearranged human light chain variable region and a murine light chain constant region, paired with a diversity of clonally unrelated rearranged immunoglobulin heavy chain variable regions, which bind said antigen; and

(b) isolating nucleic acid encoding a rearranged immunoglobulin heavy chain variable region from a B cell that produces one of said antibodies;

(c) expressing said nucleic acid encoding said rearranged immunoglobulin heavy chain variable region in a host cell together with nucleic acid encoding at least said rearranged human light chain variable region; and

(d) obtaining an antibody that binds to the antigen.

3. A method of obtaining an antibody that binds to an antigen, the method comprising

(a) isolating nucleic acid encoding a rearranged immunoglobulin heavy chain variable region from a B cell that produces an antibody that comprises a rearranged human light chain immunoglobulin variable region encoded by fused human V/J gene segments and comprises a murine constant region paired with a heavy chain variable region encoded by a rearranged and somatically hypermutated VH gene that encodes said antibody;

(b) expressing said nucleic acid encoding said rearranged immunoglobulin heavy chain variable region in a host cell together with nucleic acid encoding at least a rearranged human light chain immunoglobulin variable region encoded by fused human V/J gene segments; and

(c) obtaining an antibody which binds to the antigen,

wherein said B cell is obtained by immunizing a transgenic mouse with the antigen, wherein the genome of the transgenic mouse comprises a transgene comprising a human immunoglobulin light chain germline V gene segment fused to a human immunoglobulin light chain germline J gene segment such that there is no mutation due to said fusion, wherein the fused human V/J gene segments encode a rearranged human immunoglobulin light chain variable region and

wherein the transgene is inserted by site-specific integration in the murine Rosa locus or wherein said transgene lacks the intronic light chain enhancer MoEκi or comprises a truncation of the transgene 3′ kappa enhancer or combination of these; and

wherein the transgene comprises a murine light chain constant region gene segment or is operatively linked to an endogenous mouse light chain constant region gene segment;

wherein if the transgene is inserted by site-specific integration in the murine Rosa locus, the transgene comprises a murine light chain constant region gene segment;

wherein said transgenic mouse, in response to said antigen, produces mature B cells that secrete antibodies with immunoglobulin light chains comprising said encoded rearranged human light chain variable region and a murine light chain constant region, paired with a diversity of clonally unrelated rearranged immunoglobulin heavy chain variable regions, which bind said antigen.

Assignments (5)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
CHANGE OF ADDRESS Recorded Feb 10, 2017
From: MERUS N.V.
To: MERUS N.V.
Reel/Frame 041676/0807 →
CHANGE OF NAME Recorded Jul 12, 2016
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 039480/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2014
From: LOGTENBERG, TON; THROSBY, MARK; KRAMER, ROBERT A.; PINTO, RUI DANIEL; DE KRUIF, CORNELIS A.; HOUTZAGER, ERWIN
To: MERUS B.V.
Reel/Frame 033731/0578 →
Continuity (4)
Division 12589181 · Oct 19, 2009
Continuation 12459285 · Jun 29, 2009
Provisional Application 61133274 · Jun 27, 2008
Related Publication 20140314755A1 · Oct 23, 2014